RGLS - レグルス・セラピュ―ティクス (Regulus Therapeutics Inc.) レグルス・セラピュ―ティクス

 RGLSのチャート


 RGLSの企業情報

symbol RGLS
会社名 Regulus Therapeutics Inc (レグルス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レグルス・セラピューティクス(Regulus Therapeutics Inc.)はミクロリボ核酸(RNA)をターゲットとして種々の疾患を治療するためのファーストインクラスの薬剤の発見と開発を中心とするバイオ医薬品会社。ミクロRNAは自然発生的なリボ核酸で、重要な生物学的経路の調節に大切な役割を果たす分子である。同社はミクロRNA製品ラットフォームを使用してアンチmiRと呼ばれる、化学的に修飾された一本鎖オリゴヌクレオチドを開発する。同社はこれらアンチmiRを使用してミクロRNAを調節して、異常細胞を健康状態に返す。平成24年8月、同社は心血管疾患、代謝性疾患と腫瘍のためのミクロRNA治療薬を発見・開発するために、AstraZenecaと戦略的提携を形成した。   レグルス・セラピュ―ティクスは米国のバイオ製薬会社。マイクロRNAを標的とする医薬品の探索と開発に従事。製品は、C型肝炎感染症、心臓血管疾患、線維症、がん、メタボリックなどの治療に用いる。アストラゼネカ、グラクソスミスクライン、サノフィ、バイオジェン・アイデックなどとの戦略的提携を進める。本社はカリフォルニア州サンディエゴ。   Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
本社所在地 10614 Science Center Drive San Diego CA 92121 USA
代表者氏名 Stelios Papadopoulos Stelios Papadopoulos
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-202-6300
設立年月日 39326
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数
url www.regulusrx.com
nasdaq_url https://www.nasdaq.com/symbol/rgls
adr_tso
EBITDA EBITDA(百万ドル) -55.76000
終値(lastsale) 2.36
時価総額(marketcap) 20618213.16
時価総額 時価総額(百万ドル) 16.16258
売上高 売上高(百万ドル) 0.07200
企業価値(EV) 企業価値(EV)(百万ドル) 3.19458
当期純利益 当期純利益(百万ドル) -23.89900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Regulus Therapeutics Inc revenues remained flat at $36K. Net loss decreased 28% to $29.9M. Revenues reflect market conditions. Lower net loss reflects research decrease of 28% to $20.4M (expense) general decrease of 37% to $5.6M (expense) Stock-based Compensation in SGA decrease of 30% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$9.41 to -$3.44.

 RGLSのテクニカル分析


 RGLSのニュース

   The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx  2020/01/10 12:13:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) ( announced positive midstage results for its gene therapy to treat inherited eye disorder) Applied Therapeutics Inc (NASDAQ: APLT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) (reported positive results for a late-stage study of its peanut allergy patch) DexCom, Inc. (NASDAQ: DXCM ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Masimo Corporation (NASDAQ: MASI ) Medtronic PLC (NYSE: MDT )(announced the acquisition of Stimgenics) Molecular Templates Inc (NASDAQ: MTEM ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc.
   Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326  2019/12/16 13:00:00 PR Newswire
LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted the Partial…
   Regulus Therapeutics to Present at the Stifel Healthcare Conference  2019/11/18 13:07:00 Yahoo Finance
LA JOLLA, Calif., Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company
   Regulus Therapeutics (NASDAQ:RGLS) Posts Quarterly Earnings Results, Hits Estimates  2019/11/14 05:04:40 Modern Readers
Regulus Therapeutics (NASDAQ:RGLS) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26), Fidelity Earnings reports. Regulus Therapeutics had a negative net margin of 396.84% and a negative return on equity of 179,717.33%. The business had revenue of $0.02 million during the […]
   Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates  2019/11/12 21:05:00 PR Newswire
LA JOLLA, Calif., Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter…
   Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress(TM) 2019  2019-04-08 PR Newswire
LA JOLLA, Calif. , April 8, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical data on the therapeutic pote…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レグルス・セラピュ―ティクス RGLS Regulus Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)